Clinical Trials Directory

Trials / Completed

CompletedNCT00305448

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg

Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
143 (actual)
Sponsor
AstraZeneca · Industry
Sex
Female
Age
—
Healthy volunteers
Not accepted

Summary

This study will assess the relationship between fulvestrant dose and efficacy, and determine the dosing regimen as a second line therapy for Japanese postmenopausal women with oestrogen receptor positive advanced breast cancer.

Conditions

Interventions

TypeNameDescription
DRUGFulvestrant250 intramuscular injection
DRUGFulvestrant500 mg intramuscular injection

Timeline

Start date
2006-03-01
Primary completion
2008-03-01
Completion
2012-02-01
First posted
2006-03-22
Last updated
2012-02-15
Results posted
2011-08-29

Locations

35 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT00305448. Inclusion in this directory is not an endorsement.